Skip to Content


We have collaborated with a variety of government and industry organizations in order to develop innovative vaccines. Some of which are listed below:

BARDA - Biomedical Advanced Research and Development Authority

Altimmune was awarded a contract valued at up to $127.5 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services for the research and development of our NasoShield anthrax vaccine. The five year contract covers the manufacturing, nonclinical and clinical studies up to the Phase 3 registrational study.

National Institute of Allergy and Infectious Diseases

Altimmune was awarded contract valued at $15 million for the preclinical development of SparVax-L. The contract covers the manufacture development and preclinical safety and efficacy of the recombinant anthrax vaccine.

Kolmar Korea Co., Ltd.

Altimmune has an exclusive licensing agreement with Kolmar Korea, South Korea’s largest pharmaceutical contract manufacturing organization for marketing and sales of NasoVAX within South Korea.